Shares of Fortress Biotech Inc. (FBIO) hit a new 52-week high of $2.51 yesterday on rising investor optimism as the company prepares for a regulatory catalyst.
This biopharmaceutical company is focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings, and dividend and royalty revenue streams. Its subsidiary and partner companies that are pursuing development and/or commercialization of biopharmaceutical products and product candidates are: Journey Medical Corporation (DERM), Mustang Bio Inc. (MBIO), Avenue Therapeutics Inc. (ATXI.OB), Baergic Bio Inc., Cellvation Inc., Cyprium Therapeutics Inc., Helocyte Inc., Oncogenuity Inc., and Urica Therapeutics Inc. Checkpoint Therapeutics Inc., previously a partner company, was acquired by Sun Pharma in May 2025.
For comments and feedback: editorial@rttnews.com